查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587116

慢性阻塞性肺病治療市場：按藥物類型、產品類型、測試、應用分類 - 2025-2030 年全球預測

Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

慢性阻塞性肺病治療市場2023年估值為775億美元，預計到2024年將達到833.9億美元，複合年成長率為7.69%，預計到2030年將達到1302.4億美元。

慢性阻塞性肺病(COPD) 治療包括多種旨在控制症狀、改善生活品質和減緩疾病進展的治療方法。對有效慢性阻塞性肺病治療的需求源於這種使人衰弱的疾病的日益流行，這主要是由於空氣污染加劇、吸煙率上升和人口老化造成的。這些治療用於減少呼吸困難、預防慢性惡化並增強體力活動。最終用途範圍包括醫院、診所和家庭護理機構，使用支氣管擴張劑、皮質類固醇、氧氣療法和肺部復健等選項。慢性阻塞性肺病治療市場的關鍵成長要素包括吸入器技術的進步、針對發炎途徑的新型生技藥品的推出以及患者意識的提高。數位健康整合存在市場機會，例如遠端監控和遠端醫療平台，可以提供個人化的治療計劃和依從性支援。然而，重大挑戰仍然存在，包括高昂的藥物開發成本、嚴格的法律規範以及長期藥物治療的副作用。此外，慢阻肺早期存在許多誤診和治療不充分的情況，也阻礙了市場的拓展。創新途徑應著重於用於早期診斷的生物標記、減少全身副作用的下一代藥物傳遞系統，以及修復肺組織的細胞療法等再生醫學方法。該市場本質上是動態的，其特點是學名藥的穩定進入以及老牌製藥公司和新興生物技術公司之間的競爭。為了實現最佳業務成長，公司應優先考慮研究合作並投資以患者為中心的解決方案，以滿足個人化和微創治療中未滿足的需求。採用適應不斷變化的患者偏好和治療方法進展的敏捷方法可以增強您的市場地位並推動永續成長。

主要市場統計
基準年[2023] 775億美元
預測年份 [2024] 833.9億美元
預測年份 [2030] 1302.4億美元
複合年成長率（%） 7.69%

市場動態：快速發展的慢性阻塞性肺病治療市場的關鍵市場洞察

供需的動態交互作用正在改變慢性阻塞性肺病治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加和不健康的生活方式
    • 氣喘和慢性阻塞性肺病（COPD）患者數量不斷增加
    • 消費者對數位氣喘護理設備的認知不斷增強
  • 市場限制因素
    • 政府對吸入器核准有嚴格的規定
  • 市場機會
    • 氣喘治療設備和新產品發布的快速技術進步
    • 居家照護治療設備需求旺盛
  • 市場挑戰
    • 吸入器的價格壓力不斷增加且專利到期

波特五力：開拓慢性阻塞性肺病治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解慢性阻塞性肺病治療市場的外部影響

外部宏觀環境因素在塑造慢性阻塞性肺病治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解慢性阻塞性肺病治療市場的競爭格局

對慢性阻塞性肺病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣慢性阻塞性肺病治療市場供應商的績效評估

FPNV 定位矩陣是評估慢性阻塞性肺病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃慢性阻塞性肺病治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對慢性阻塞性肺病治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口增加和不健康的生活方式
      • 氣喘和慢性阻塞性肺病(COPD) 的地理定位數
      • 意識提升對數位氣喘護理設備的認知
    • 抑制因素
      • 政府對吸入器核准的嚴格規定
    • 機會
      • 氣喘治療設備和新產品發布的快速技術進步
      • 居家照護治療設備需求量大
    • 任務
      • 吸入器的價格壓力不斷增加且專利到期
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章慢性阻塞性肺病治療市場（依藥物類型）

  • 抗生素
  • 抗膽鹼能藥
  • BETA2促效劑
  • 甲基黃嘌呤類
  • 口服類固醇
  • 磷酸二酯酶4抑制劑

第7章慢性阻塞性肺病治療市場：依產品

  • 吸入器
  • 噴霧器

第8章慢性阻塞性肺病治療市場測試

  • 動脈血氣測試
  • 胸部X光檢查
  • 電腦斷層掃描
  • 基因檢測
  • 肺功能檢查

第9章慢性阻塞性肺病治療市場：依應用分類

  • 慢性支氣管炎
  • 氣腫
  • 難治性氣喘

第10章北美及南美洲慢性阻塞性肺病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區慢性阻塞性肺病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲慢性阻塞性肺病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Adamis Pharmaceuticals Corporation
  • Almirall, SA
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Oyj
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43676CF42C41

The Chronic Obstructive Pulmonary Disease Treatment Market was valued at USD 77.50 billion in 2023, expected to reach USD 83.39 billion in 2024, and is projected to grow at a CAGR of 7.69%, to USD 130.24 billion by 2030.

Chronic Obstructive Pulmonary Disease (COPD) treatment encompasses an array of therapeutic approaches aimed at managing symptoms, improving quality of life, and slowing disease progression. The necessity for effective COPD treatments arises from the rising prevalence of this debilitating disease, largely driven by increased air pollution, smoking rates, and an aging population. These treatments find application in reducing breathlessness, preventing chronic exacerbations, and enhancing physical activity. The end-use scope includes hospitals, clinics, and home care settings, where options such as bronchodilators, corticosteroids, oxygen therapy, and pulmonary rehabilitation are utilized. Key growth influencers in the COPD treatment market include advancements in inhaler technologies, the introduction of novel biologics targeting inflammatory pathways, and increasing patient awareness. Market opportunities lie within the digital health integration-like remote monitoring and telemedicine platforms-offering personalized treatment plans and adherence support. However, substantial challenges remain, such as high drug development costs, stringent regulatory frameworks, and the adverse side effects of long-term pharmacotherapy. Additionally, the frequent misdiagnosis and under-treatment in early-stage COPD hinder market expansion. Innovation avenues should focus on biological markers for early diagnosis, next-generation drug delivery systems reducing systemic side effects, and regenerative medicine approaches like cellular therapies aimed at lung tissue restoration. The market is inherently dynamic, characterized by a steady entry of generic products and the competition between established pharmaceutical players and emerging biotechnology firms. For optimal business growth, companies should prioritize research collaborations and invest in patient-centric solutions addressing unmet needs in personalized and minimally invasive therapies. Embracing an agile approach that aligns with evolving patient preferences and therapeutic advancements will enhance market position and drive sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 77.50 billion
Estimated Year [2024] USD 83.39 billion
Forecast Year [2030] USD 130.24 billion
CAGR (%) 7.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in geriatric population and rise in unhealthy lifestyle
    • Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
    • Increasing consumer awareness toward digital asthma care devices
  • Market Restraints
    • Stringent regulations for inhaler approvals by the government
  • Market Opportunities
    • Rapid technological advancements and new product launches in the asthma devices
    • High demand for home care therapeutic devices
  • Market Challenges
    • Increased pricing pressures and patent expiries on inhalers

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Obstructive Pulmonary Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Obstructive Pulmonary Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Obstructive Pulmonary Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Obstructive Pulmonary Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Obstructive Pulmonary Disease Treatment Market

A detailed market share analysis in the Chronic Obstructive Pulmonary Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Obstructive Pulmonary Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Obstructive Pulmonary Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Obstructive Pulmonary Disease Treatment Market

A strategic analysis of the Chronic Obstructive Pulmonary Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Obstructive Pulmonary Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, S.A., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Orion Oyj, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chronic Obstructive Pulmonary Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antibiotic, Anticholinergic, Beta2-agonists, Methylxanthines, Oral Corticosteroid, and Phosphodiesterase-4 Inhibitors.
  • Based on Product, market is studied across Inhalers and Nebulizers.
  • Based on Test, market is studied across Arterial Blood Gas Test, Chest X-ray Test, CT scan, Genetic Test, and Lung Functional Test.
  • Based on Application, market is studied across Chronic Bronchitis, Emphysema, and Refractory Asthma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in geriatric population and rise in unhealthy lifestyle
      • 5.1.1.2. Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
      • 5.1.1.3. Increasing consumer awareness toward digital asthma care devices
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations for inhaler approvals by the government
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid technological advancements and new product launches in the asthma devices
      • 5.1.3.2. High demand for home care therapeutic devices
    • 5.1.4. Challenges
      • 5.1.4.1. Increased pricing pressures and patent expiries on inhalers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antibiotic
  • 6.3. Anticholinergic
  • 6.4. Beta2-agonists
  • 6.5. Methylxanthines
  • 6.6. Oral Corticosteroid
  • 6.7. Phosphodiesterase-4 Inhibitors

7. Chronic Obstructive Pulmonary Disease Treatment Market, by Product

  • 7.1. Introduction
  • 7.2. Inhalers
  • 7.3. Nebulizers

8. Chronic Obstructive Pulmonary Disease Treatment Market, by Test

  • 8.1. Introduction
  • 8.2. Arterial Blood Gas Test
  • 8.3. Chest X-ray Test
  • 8.4. CT scan
  • 8.5. Genetic Test
  • 8.6. Lung Functional Test

9. Chronic Obstructive Pulmonary Disease Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Chronic Bronchitis
  • 9.3. Emphysema
  • 9.4. Refractory Asthma

10. Americas Chronic Obstructive Pulmonary Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adamis Pharmaceuticals Corporation
  • 3. Almirall, S.A.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 8. Chiesi Farmaceutici S.p.A.
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline Plc
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Orion Oyj
  • 15. Sunovion Pharmaceuticals Inc.
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA2-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ARTERIAL BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHEST X-RAY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LUNG FUNCTIONAL TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REFRACTORY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023